Skip to main content

Dexcom Value Stock - Dividend - Research Selection

Dexcom

ISIN: US2521311074 , WKN: A0D9T1

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Did FDA-App Recalls and Activist Pressure Just Rewire Dexcom’s (DXCM) Software-Driven Investment Narrative?

2026-06-03
In May 2026, Dexcom disclosed FDA-enforced, Class II voluntary recalls of its G7 and ONE/ONE+ iOS and watchOS apps worldwide due to a software defect that can delay or replay glucose readings and alerts, potentially leading users to act on outdated data. The recalls highlight the growing importance of Dexcom’s software quality and real-time data integrity, especially as its CGM ecosystem becomes more deeply embedded in everyday diabetes management across multiple countries and devices. We’ll...

2 Growth Stocks to Buy and Hold for a Decade

2026-06-02
They have outpaced the S&P 500 over the past 10 years.

TNDM Stock: What to Know About Tandem's 2026 Reset

2026-06-02
Tandem Diabetes' Q1 beat, fatter margins and positive cash flow fuel its 2026 reset as it shifts more U.S. pump starts to pay-as-you-go pharmacy.

Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience

2026-06-02
SAN DIEGO, June 02, 2026--Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, healthcare professionals and community leaders, along with clear, actionable company commitments to further elevate product performance and user experience. Building on its position as the manufacturer of the most accurate CGM systems1, Dexcom continues to listen, innovate and act on customer insights to

Citigroup Maintains Buy on DexCom, Raises Price Target to $84

2026-05-28
Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $79 to $84.

Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners

2026-05-28
SAN FRANCISCO, May 28, 2026--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the expansion of Hims & Hers Benefits, adding eight new partners to the Hims & Hers exclusive program. Joining founding partners Prenuvo and Eight Sleep are Natural Cycles, MyFitnessPal, Ladder, PVOLVE Studios, HelloFresh, Factor, Flo Health, Dexcom, and iFIT - a carefully curated lineup spanning nutrition, fitness, women's health, metabolic monitoring, and connected well

U.S.-Iran strikes, Snowflake soars, Robinhood's new AI tools and more in Morning Squawk

2026-05-28
Here are five key things investors need to know to start the trading day.

Signos CEO talks using AI to power its drug-free weight loss tool

2026-05-27
Sharam Fouladgar-Mercer, Signos CEO, joins 'Fast Money' to talk its latest funding round for its drug-free weight loss tool.

How The DexCom (DXCM) Investment Story Is Shifting With New Guidance And Valuation Resets

2026-05-27
DexCom’s latest valuation work now centers on a fair value anchor of US$81.64, slightly below the prior US$83.54 level and closer to the current range of Street targets. Many firms have trimmed price targets after recent Analyst/Investor Day updates, reflecting a balance between confidence in execution and a more cautious stance on longer term growth and valuation assumptions. As you read on, you will see how these shifting targets, together with fresh guidance and product news, shape the...

Signos raises $20M, expands Dexcom partnership for weight loss

2026-05-27
Google Ventures, Dexcom, and Blue Cross Blue Shield of Alabama backed the round as demand for weight loss tools grows